Medtronic PLC $MDT Stock: Edmond DE Rothschild Holding S.A. Boosts Position

Edmond DE Rothschild Holding S.A. boosted its position in shares of Medtronic PLC (NYSE:MDT – Free Report) by 8.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 688,142 shares of the medical technology company’s stock after buying an additional 52,693 shares during the period. Edmond DE Rothschild Holding S.A. owned approximately 0.05% of Medtronic worth $59,380,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in MDT. First Eagle Investment Management LLC raised its holdings in shares of Medtronic by 37.2% during the 2nd quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock worth $1,078,321,000 after acquiring an additional 3,739,288 shares in the last quarter. Cullen Capital Management LLC bought a new stake in shares of Medtronic in the 2nd quarter worth about $202,764,000. State Street Corp increased its holdings in shares of Medtronic by 2.7% in the 2nd quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock worth $5,005,320,000 after buying an additional 1,658,301 shares during the last quarter. Amundi raised its position in shares of Medtronic by 36.3% during the 1st quarter. Amundi now owns 6,070,236 shares of the medical technology company’s stock valued at $525,986,000 after buying an additional 1,616,739 shares in the last quarter. Finally, Bank of America Corp DE raised its position in shares of Medtronic by 5.4% during the 1st quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company’s stock valued at $2,254,200,000 after buying an additional 1,343,220 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Recent Medtronic Headlines

These are some of the MDT headlines that stood out recently:

  • Positive Sentiment: Analyst coverage points to growth potential from adoption of Medtronic’s Hugo surgical robot, international expansion and Neuroscience products. A separate report projects strong growth in connected health devices through 2032, a market that includes Medtronic. Medtronic growth prospects Connected health devices market report
  • Neutral Sentiment: A preview of Medtronic’s fiscal second-quarter results focused on expected metrics but did not report actual results, leaving investors awaiting the earnings update. Medtronic Q2 earnings preview
  • Negative Sentiment: The outlook discussion also flags margin and currency headwinds, which could limit the benefit of growth in Hugo, international markets and Neuroscience. Medtronic hold analysis

Medtronic Trading Down 0.1%

Shares of NYSE MDT opened at $100.57 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07. The business’s 50 day moving average price is $94.44 and its 200-day moving average price is $88.47. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The company has a market cap of $128.64 billion, a price-to-earnings ratio of 24.77, a PEG ratio of 2.36 and a beta of 0.56.

Medtronic (NYSE:MDT – Get Free Report) last posted its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. The company had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. Medtronic’s revenue was up 13.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, sell-side analysts expect that Medtronic PLC will post 5.98 earnings per share for the current year.

Insider Transactions at Medtronic

In related news, EVP Harry Kiil sold 1,483 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total value of $138,882.95. Following the transaction, the executive vice president owned 42,186 shares of the company’s stock, valued at $3,950,718.90. This trade represents a 3.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Geoffrey Martha sold 50,000 shares of Medtronic stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the sale, the chief executive officer owned 277,866 shares of the company’s stock, valued at $26,397,270. The trade was a 15.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 61,903 shares of company stock worth $5,889,203. 0.27% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts recently commented on the company. BTIG Research lifted their price target on Medtronic from $99.00 to $109.00 and gave the stock a “buy” rating in a research report on Thursday. Mizuho set a $115.00 price objective on Medtronic in a research note on Wednesday, September 2nd. TD Cowen set a $110.00 target price on Medtronic and gave the stock a “buy” rating in a report on Tuesday. Bank of America boosted their target price on Medtronic from $95.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, September 2nd. Finally, Stifel Nicolaus increased their price target on Medtronic from $80.00 to $95.00 and gave the company a “hold” rating in a report on Wednesday, September 2nd. Eighteen investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.17.

View Our Latest Research Report on MDT

Medtronic Company Profile

(Free Report)

Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.

Featured Articles

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.